Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q4 FY23 results · Jan–Mar 2023
Alkem Laboratories reported revenue from operations of ₹2,902.60 crore (up 16.9% from Q4 FY22) and net profit of ₹67.68 crore (down 37.5% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,902.60 | 2,483.86 | +16.9% | 3,040.91 | −4.5% |
| Other income | 68.67 | 20.52 | +234.6% | 45.33 | +51.5% |
| Total income | 2,971.27 | 2,504.38 | +18.6% | 3,086.24 | −3.7% |
| Profit before tax | 211.66 | 242.68 | −12.8% | 538.89 | −60.7% |
| Net profit for the period | 67.68 | 108.21 | −37.5% | 459.96 | −85.3% |
| Attributable to shareholders of the company | 70.98 | 107.58 | −34.0% | 454.71 | −84.4% |
| EPS, basic (₹) | 5.94 | 9.00 | −34.0% | 38.03 | −84.4% |
| Net margin (%) | 2.3 | 4.4 | 15.1 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,237.99 | 2,006.31 | +11.5% | 2,296.72 | −2.6% |
| Other income | 76.60 | 54.23 | +41.3% | 60.74 | +26.1% |
| Total income | 2,314.59 | 2,060.54 | +12.3% | 2,357.46 | −1.8% |
| Profit before tax | 329.69 | 185.83 | +77.4% | 435.95 | −24.4% |
| Net profit for the period | 254.79 | 76.88 | +231.4% | 388.89 | −34.5% |
| EPS, basic (₹) | 21.31 | 6.43 | +231.4% | 32.52 | −34.5% |
| Net margin (%) | 11.4 | 3.8 | 16.9 |
Consolidated
- Filed with BSE
- 22 May 2023, 11:50 IST
- Board meeting
- 19 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 May 2023, 11:50 IST
- Board meeting
- 19 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE